Diabetes patients in the US will have greater flexibility in managing insulin delivery after Insulet announced its Omnipod pump is now compatible with Abbott’s FreeStyle Libre 2 Plus continuous ...

Abbott announced yesterday that its recently cleared FreeStyle Libre 2 integrated continuous glucose monitoring (CGM) system is now covered by the Centers for Medicare and Medicaid Services (CMS), and ...

Data from Abbott’s REFLECT study show for the first time that the use of its continuous glucose monitoring technology, Freestyle Libre, can help lessen the severity of cardiovascular complications in ...

Abbott has recalled the FreeStyle Libre Glucose Monitors due to the risk of extreme heat and fire. The FDA has identified the recall as Class 1, the most severe type of recall. Product models consist ...

The FreeStyle Libre 3 system is the most accurate 14-day continuous glucose monitor1, with readings sent directly to a smartphone every minute.2 Designed for access and affordability, the FreeStyle ...

They say a rising tide lifts all boats, and that certainly seems to be the case with the new wave of drugs and devices for diabetes management. In a recent analysis (PDF), Abbott examined trends in ...

A major wrongful death lawsuit has been filed alleging defects in Abbott Laboratories' (NYSE:ABT) FreeStyle Libre 3 and Libre 3 Plus glucose monitoring systems. The claim links the products to seven ...

Key collaborations enable Abbott to increase its global presence and accessibility to patients who haven't used CGMs before, potentially resulting in a 15% CAGR in FreeStyle Libre sales by 2028. With ...

Please provide your email address to receive an email when new articles are posted on . A voluntary medical device correction warned users of three Abbott FreeStyle Libre readers about the risk of ...

Pharmaceutical and med device giant Abbott (NYSE: ABT) said today that it had received approval from the Food and Drug Administration (FDA) for its next-generation integrated continuous glucose ...

Abbott announced new late-breaking data demonstrating use of its FreeStyle Libre system, the world's leading sensor-based glucose monitoring technology, is associated with significant reduction in ...

Abbott Labs’ (NYSE:ABT) stock price could gain over 10% if its FreeStyle Libre system captures a 30% share of the blood glucose monitoring market by 2020, according to our estimates. FreeStyle Libre ...